Induction of Donor-Specific Tolerance Using Superagonistic CD28 Antibody in Rat Renal Allografts: Regulatory T-Cell Expansion Before Engraftment May Be Important
- 27 December 2010
- journal article
- research article
- Published by Wolters Kluwer Health in Transplantation
- Vol. 90 (12) , 1328-1335
Abstract
Background. We hypothesized that a superagonistic monoclonal antibody specific for CD28 (CD28SA), which expands regulatory T cells (Tregs) in vivo, would prevent acute rejection and prolong the survival of renal allograft. Methods. We examined whether CD28SA treatment induce donor-specific tolerance using our established rat renal allograft model (Wistar-Lewis). Results. All control rats died within 13 days because of severe azotemia with marked destruction of graft tissue. In contrast, recipients treated with a triple injection of CD28SA (days −3, 0, and 3) showed good preservation of graft histology and function, with considerable infiltration of Tregs into the allografts; 92% of recipients survived for more than 100 days, and 77% survived by the day of harvest at 180 days. These long-surviving recipients received secondary heterotopic bicardiac allografts from both donor-matched Wistar and third-party Brown Norway rats simultaneously 120 days after kidney transplantation, and seven of eight (87.5%) rats exhibited donor-specific tolerance, accepting the Wistar heart, but acutely rejecting the Brown Norway heart. Interestingly, a single injection of CD28SA 3 days before (day −3), but not 3 days after (day 3), transplantation also induced donor-specific tolerance in some recipients. We then performed adoptive transfer of nonspecific CD4+CD25+ Tregs, purified from CD28SA-treated Lewis rats, with simultaneous injection of hepatocyte growth factor (500 μg/kg/day, intravenously). The treatment induced significant prolongation of graft survival (P<0.0001 vs. control group), and five of eight (62.5%) recipients survived until the day of harvest at 180 days with successful induction of donor-specific tolerance. Conclusions. We have established a novel therapeutic approach for inducing donor-specific tolerance in rats with renal allografts.Keywords
This publication has 27 references indexed in Scilit:
- Superagonist CD28 Antibody Preferentially Expanded Foxp3-Expressing nTreg Cells and Prevented Graft-Versus-Host DiseasesCell Transplantation, 2009
- Superagonistic CD28 Antibody Induces Donor-Specific Tolerance in Rat Renal AllograftsAmerican Journal of Transplantation, 2008
- Foxp3-expressing Regulatory T Cells Expanded With CD28 Superagonist Antibody Can Prevent Rat Cardiac Allograft RejectionThe Journal of Heart and Lung Transplantation, 2008
- Selective targeting of regulatory T cells with CD28 superagonists allows effective therapy of experimental autoimmune encephalomyelitisJournal of Experimental Medicine, 2005
- Crystal structure of a soluble CD28-Fab complexNature Immunology, 2005
- CD28, Costimulator or Agonist Receptor?Journal of Experimental Medicine, 2003
- Topological Requirements and Signaling Properties of T Cell–activating, Anti-CD28 Antibody SuperagonistsJournal of Experimental Medicine, 2003
- Transfection of NFκB-decoy oligodeoxynucleotides using efficient ultrasound-mediated gene transfer into donor kidneys prolonged survival of rat renal allograftsGene Therapy, 2003
- CD28‐mediated induction of proliferation in resting T cells in vitro and in vivo without engagement of the T cell receptor: Evidence for functionally distinct forms of CD28European Journal of Immunology, 1997
- Long-term acceptance of major histocompatibility complex mismatched cardiac allografts induced by CTLA4Ig plus donor-specific transfusion.Journal of Experimental Medicine, 1993